fingolimod hydrochloride has been researched along with dimethyl fumarate in 144 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (dimethyl fumarate) | Trials (dimethyl fumarate) | Recent Studies (post-2010) (dimethyl fumarate) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 1,047 | 71 | 886 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (0.69) | 29.6817 |
| 2010's | 83 (57.64) | 24.3611 |
| 2020's | 60 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Burton, JM; O'Connor, P | 1 |
| Fontoura, P; Garren, H | 1 |
| Gold, R | 1 |
| Csépány, T | 1 |
| Killestein, J; Polman, CH; Rudick, RA | 1 |
| Graham-Rowe, D | 1 |
| Ais-Larisgoitia, A; de Lorenzo-Pinto, A; Rodríguez-González, CG | 1 |
| Fox, RJ | 1 |
| Agarwal, S; Deniz, B; Fox, RJ; Havrdova, E; Hutchinson, M; Kurukulasuriya, NC; Sarda, SP; Siddiqui, MK; Taneja, A | 1 |
| Alwan, S; Dahlgren, L; Lu, E; Sadovnick, AD; Synnes, A; Tremlett, H; Wang, BW | 1 |
| Sorensen, PS | 1 |
| di Nuzzo, L; Nasca, C; Nicoletti, F; Orlando, R | 1 |
| Lovett-Racke, AE; Racke, MK; Yang, Y | 1 |
| Carrithers, MD | 1 |
| Bridel, C; Lalive, PH | 1 |
| McDonald, EA; Sedal, L; Wilson, IB | 1 |
| Hay, JW; Niu, X; Zhang, X | 1 |
| Moses, H | 1 |
| Bergvall, N; Cutter, G; Giovannoni, G; Nixon, R; Sfikas, N; Tomic, D | 1 |
| Thomas, RH; Wakefield, RA | 1 |
| Carreón-Guarnizo, E; Hernández-Clares, R; Meca-Lallana, JE | 1 |
| Aloi, JJ; English, C | 1 |
| Bagnato, F; Pawate, S | 1 |
| Cocco, E; Coghe, GC; Fenu, G; Frau, J; Lorefice, L; Marrosu, MG | 1 |
| Cocco, E; Coghe, GC; Fenu, G; Frau, F; Lorefice, L; Marrosu, MG | 1 |
| Adlard, N; Bergvall, N; Griffiths, MJ; Maruszczak, MJ; Montgomery, SM | 1 |
| Gielen, J; Laton, J; Nagels, G; Van Schependom, J | 1 |
| Harel, A; Lublin, F; Straus Farber, R | 1 |
| de Bruin, NM; Geisslinger, G; Häußler, A; Jordan, H; Parnham, MJ; Schiffmann, S; Schmidt, M; Schmitz, K; Tafferner, N; Tegeder, I | 1 |
| Aktas, O; Hartung, HP; Ingwersen, J | 1 |
| Fay, M; Iyer, R; Livingston, T; Mauskopf, J; Sarda, S | 1 |
| Iljicsov, A; Pál, Z; Simó, M | 1 |
| Basuki, MA; Booth, DR; Burke, T; Fabis-Pedrini, MJ; Fewings, N; Gatt, PN; Goldinger, A; Kermode, AG; McKay, FC; Parnell, GP; Powell, JE; Schibeci, SD; Stewart, GJ; Vucic, S | 1 |
| Al-Khamis, FA | 1 |
| Kretzschmar, B; Pellkofer, H; Weber, MS | 1 |
| Berer, K; Bradl, M; Feil, K; Gürkov, R; Hohlfeld, R; Krane, M; Krumbholz, M; Kümpfel, T; Lahm, H; Lange, R; Meinl, E; Meinl, I; Mulazzani, M; Pfannes, K; Schuh, E; Subklewe, M | 1 |
| Weinshenker, BG; Wingerchuk, DM | 1 |
| Flood, E; Katic, B; Nafees, B; Rasouliyan, L; Sasané, R; Wicks, P | 1 |
| Chard, D; Chataway, J; Trip, A | 1 |
| Chan, A; Edwards, MR; Fox, RJ; Levison, D; Lewin, JB; Marantz, JL; Xiao, J; Zhang, A | 1 |
| Al Hail, H; Bhagat, A; Canibano, B; Deleu, D; El Khider, H; Hanssens, Y; Ibrahim, F; Melikyan, G; Mesraoua, B; Mhjob, N | 1 |
| Dive-Pouletty, C; Freedman, MS; Hass, S; Leist, TP; Miller, AE; Montalban, X; Thangavelu, K | 1 |
| Bermel, RA; Cohen, JA; Cohn, S; Fox, RJ; Hara-Cleaver, C; Hersh, CM; Love, TE; Ontaneda, D | 1 |
| Kulkarni, P; Medishetti, R; Saxena, U; Sriram, D; Yellanki, S; Yogeeswari, P | 1 |
| Tyor, WR; Vargas, DL | 1 |
| Fischetti, VA; Rumah, KR; Vartanian, TK | 1 |
| Adlard, N; Allen, F; Bending, M; Firth, Z; Huisman, E; Jarrett, J; Papadimitropoulou, K | 1 |
| Bergamaschi, R; Boiocchi, C; Cuccia, M; Mallucci, G; Osera, C; Pascale, A; Pistono, C | 1 |
| Miller, A; Staun-Ram, E | 1 |
| Dashputre, AA; Kamal, KM; Pawar, G | 1 |
| Herrera, V; Johnson, KM; Ko, JJ; Lin, F; Zhou, H | 1 |
| Bramanti, P; Guarnera, C; Mazzon, E | 1 |
| Carlini, G; Cerqua, R; Danni, M; Lattanzi, S; Provinciali, L; Pulcini, A; Silvestrini, M; Taffi, R | 1 |
| Chataway, J; Doshi, A | 1 |
| Baharnoori, M; Chitnis, T; Chua, A; Diaz-Cruz, C; Gonzalez, CT; Healy, BC; Stankiewicz, J; Weiner, HL | 1 |
| Boremalm, M; Frisell, T; Granqvist, M; Piehl, F; Poorghobad, A; Salzer, J; Svenningsson, A | 1 |
| Eriksson, I; Komen, J; Malmström, RE; Piehl, F; von Euler, M; Wettermark, B | 1 |
| Faissner, S; Gold, R | 1 |
| Aoyama, S; Kuwabara, S; Masuda, H; Mori, M; Ohtani, R; Uchida, T; Uzawa, A | 1 |
| Correale, J | 1 |
| Buc, M | 1 |
| Banzi, R; Bertele', V; Garattini, S; Gerardi, C; Rossi, S | 1 |
| Giacomini, PS | 1 |
| Fukazawa, T; Kawashima, A; Miyazaki, Y; Niino, M; Sato, K; Yamada, M | 1 |
| Bellantonio, P; Bianco, A; Buscarinu, MC; Buttari, F; Centonze, D; Cortese, A; De Giglio, L; Fantozzi, R; Ferraro, E; Fornasiero, A; Francia, A; Galgani, S; Gasperini, C; Haggiag, S; Lucchini, M; Marfia, GA; Millefiorini, E; Mirabella, M; Nociti, V; Pontecorvo, S; Pozzilli, C; Prosperini, L; Ruggieri, S; Salvetti, M; Sgarlata, E | 1 |
| Blizzard, L; Chen, J; Palmer, AJ; Simpson, S; Taylor, BV; van der Mei, IAF | 1 |
| Adlard, NE; Kroes, MA; Montgomery, SM; Noon, KM | 1 |
| Mitsikostas, DD; Papadopoulos, D | 1 |
| Bergmann, A; Braune, S; Freudensprung, U; Grimm, S; Hyde, R; Pellegrini, F; van Hövell, P | 1 |
| Babb, J; Carraro, M; Hou, Q; Jhaveri, M; Livingston, T; Mendoza, JP; Nicholas, J; Ontaneda, D; Riester, K; Zhou, J | 1 |
| Carruthers, R; Evans, C; Kingwell, E; Marrie, RA; Setayeshgar, S; Tremlett, H; Zhang, T; Zhu, F | 1 |
| Chitnis, T; Choudhry, NK; Desai, RJ; Gagne, JJ; Hurley, E; Mahesri, M; Matlin, OS; Minden, S; Shrank, WH; Spettell, CM; Tong, A | 1 |
| Cheong, WL; Yoon, EL | 1 |
| Alroughani, R; Ampapa, R; Bergamaschi, R; Boz, C; Butler, E; Butzkueven, H; Duquette, P; Ferraro, D; Girard, M; Grammond, P; Grand'Maison, F; Granella, F; Hodgkinson, S; Horakova, D; Izquierdo, G; Jokubaitis, V; Kalincik, T; Kappos, L; Karabudak, R; Kubala Havrdova, E; Kuhle, J; Lechner-Scott, J; Lugaresi, A; McCombe, PA; Onofrj, M; Ozakbas, S; Pesch, VV; Prat, A; Prevost, J; Pucci, E; Ramo-Tello, C; Sánchez-Menoyo, JL; Shaygannejad, V; Slee, M; Sola, P; Solaro, C; Spelman, T; Spitaleri, D; Terzi, M; Trojano, M; Turkoglu, R; Van Wijmeersch, B; Vucic, S; Yamout, B | 1 |
| Duquette, P; Haddad, P; Mouallif, S; Nakhaipour, HR; Schecter, R; Yeung, M | 1 |
| Harding, K; Hrastelj, J; Joseph, F; Pickersgill, T; Rimmer, A; Robertson, N; Tallantyre, E; Tomassini, V; Wardle, M; Williams, O; Willis, M | 1 |
| Alonso-Magdalena, L; Dangond, F; Galazka, A; Martinelli, V; Pfleger, C; Phillips, L; Rieckmann, P; Vermersch, P | 1 |
| Alvarez, E; Corboy, JR; Nair, KV; Sillau, S; Vollmer, BL; Vollmer, T | 1 |
| Berger, T; Enzinger, C; Guger, M; Kalcher, S; Kraus, J; Kvas, E; Leutmezer, F | 2 |
| Al Khedr, A; Barbin, L; Berger, E; Bourre, B; Brassat, D; Brochet, B; Cabre, P; Camdessanché, JP; Casey, R; Casez, O; Clavelou, P; De Sèze, J; Debouverie, M; Debroucker, T; Defer, G; Edan, G; Foucher, Y; Gout, O; Guennoc, AM; Heinzlef, O; Labauge, P; Labeyrie, C; Laplaud, DA; Lebrun-Frenay, C; Leray, E; Lubetzki, C; Magy, L; Maubeuge, N; Michel, L; Moreau, T; Nifle, C; Papeix, C; Patry, I; Pelletier, J; Rollot, F; Stankoff, B; Thouvenot, E; Tourbah, A; Vermersch, P; Vukusic, S; Wahab, A; Wiertlewski, S | 1 |
| Brieva, L; Cano, A; Hervás-García, JV; Mansilla, MJ; Martínez-Cáceres, EM; Moral-Torres, E; Munteis, E; Navarro-Barriuso, J; Presas-Rodriguez, S; Quirant-Sánchez, B; Ramo-Tello, C; Teniente-Serra, A | 1 |
| Décard, BF; Derfuss, T; Diebold, M; Fischer-Barnicol, B; Kappos, L; Kuhle, J; Tsagkas, C | 1 |
| Alvarez, E; Bermel, RA; Cohen, JA; Corboy, JR; Fox, RJ; Harris, H; Hersh, CM; Nair, K; Ontaneda, D; Vollmer, B; Vollmer, T | 1 |
| Brück, W; Grondey, K; Häusser-Kinzel, S; Husseini, L; Pellkofer, HL; Rowold, C; Seeger, I; Traub, JW; Weber, MS | 1 |
| Briner, M; Chan, A; Daponte, A; Diem, L; Evangelopoulos, ME; Findling, O; Gold, R; Hoepner, R; Kilidireas, C; Miclea, A; Salmen, A | 1 |
| Arlauskienė, A; Laužikienė, D; Ramašauskaitė, D; Varytė, G; Zakarevičienė, J | 1 |
| Bergmann, A; Braune, S; Heer, Y; Jules, E; Lionetto, F; Stühler, E; van Hövell, P; Westermann, C | 1 |
| Benedetti, MD; Calabria, F; Farina, G; Forgione, A; Forlivesi, S; Gajofatto, A; Marangi, A; Marchioretto, F; Rossi, F; Stenta, G; Vianello, M; Vicenzi, V | 1 |
| Carruthers, R; Kingwell, E; Marrie, RA; Ng, HS; Tremlett, H; Zhang, T; Zhu, F | 1 |
| Boffa, G; Bruschi, N; Capello, E; Cellerino, M; Inglese, M; Lapucci, C; Novi, G; Sbragia, E; Uccelli, A | 1 |
| Annovazzi, P; Baroncini, D; Barone, S; Barrilà, C; Binello, E; Bonavita, S; Carmisciano, L; Cerqua, R; Clerico, M; Cocco, E; Cordioli, C; Di Sapio, A; Frau, J; Frigeni, B; Grasso, R; Gutierrez, LP; Ippolito, D; La Gioia, S; Landi, D; Lanzillo, R; Laroni, A; Lavorgna, L; Maniscalco, GT; Mataluni, G; Perini, P; Pontecorvo, S; Rasia, S; Repice, A; Russo, CV; Saccà, F; Sartori, A; Signori, A; Signoriello, E; Sormani, MP; Stromillo, ML; Torri Clerici, V; Turano, G; Zarbo, IR | 1 |
| Kondo, T | 1 |
| Bowen, JD; Brink, J; Brown, TR; Lucassen, EB; Repovic, P; Smoot, K; Wundes, A | 1 |
| Azimi, AR; Nourbakhsh, B; Safavi, F | 1 |
| Amor, S; Baker, D; Giovannoni, G; Kang, AS; Schmierer, K | 1 |
| Filippi, M; Preziosa, P; Rocca, MA | 1 |
| Abdelhak, A; Hemmer, B; Kemmerer, CL; Kowarik, MC; Krumbholz, M; Pernpeintner, V; Ruschil, C; Scholl, M; Ziemann, U | 1 |
| Alvarez, E; Corboy, JR; Nair, K; Sillau, S; Vollmer, BL; Vollmer, T | 1 |
| Ahmed, SF; Alroughani, R; Ibrahim Ismail, I; Salama, S | 1 |
| Benkert, P; Derfuss, T; Hänni, P; Kappos, L; Kuhle, J; Lienert, C; Lorscheider, J; Yaldizli, Ö | 1 |
| Comi, G; Dalla Costa, G; Moiola, L | 1 |
| Abdoli Shadbad, M; Ayromlou, H; Baghbani, E; Baradaran, B; Jigari-Asl, F; Khamiriyan, M; Khaze Shahgoli, V; Noorolyai, S; Rahmani, S; Safaralizadeh, R; Shanehbandi, D | 1 |
| Bryll, A; Drabik, L; Karcz, P; Kolasinska, J; Kolasinska, M; Marona, M; Popiela, T; Skladzien, J; Slowik, A; Szaleniec, J; Wnuk, M; Ziekiewicz, M | 1 |
| Carruthers, R; Evans, C; Kingwell, E; Marrie, RA; Tremlett, H; Walld, R; Zhang, T; Zhu, F | 1 |
| Battaglia, MA; Capobianco, M; Carmisciano, L; Comi, G; Cordioli, C; De Rossi, N; Immovilli, P; Moiola, L; Patti, F; Radaelli, M; Salvetti, M; Schiavetti, I; Sormani, MP; Tedeschi, G; Trojano, M; Zaratin, P | 1 |
| Delgado, S; Hernandez, J; Rammohan, K; Tornes, L | 1 |
| Capone, F; Di Lazzaro, V; Ferraro, E; Motolese, F | 1 |
| Doi, H; Fukai, R; Higashiyama, Y; Morihara, K; Nakamura, H; Takahashi, K; Takahashi, T; Takeuchi, H; Tanaka, F | 1 |
| Altincatal, A; Berdofe, A; Centonze, D; de Moor, C; Jung, E; Kim, M; Nagpal, A; Naylor, ML; Popescu, C; Radhakrishnan, M; Rajbhandari, R; Reder, AT; Sandrock, AW; Smirnakis, K | 1 |
| Jacobs, D; Pham Nguyen, TP; Thibault, D; Willis, AW | 1 |
| Callegari, I; Derfuss, T; Galli, E | 1 |
| Espinosa-Rosso, R; Gil-Bernal, R; Gómez-Gómez, C; González-Caballero, JL | 1 |
| Galetta, K; George, IC; Gillani, RL; Ham, AS; Hotan, GC; Hutto, SK; Kaplan, TB; Klawiter, EC; Mateen, FJ; Matiello, M; Rice, DR; Vogel, AC | 1 |
| Abouelfath, A; Blin, P; Bosco-Lévy, P; Brochet, B; Debouverie, M; Diez, P; Droz-Perroteau, C; Guillemin, F; Heinzlef, O; Lassalle, R; Lignot, S; Louapre, C; Maillart, E | 1 |
| Häusler, D; Häusser-Kinzel, S; Ochs, J; Quendt, C; Weber, MS | 1 |
| Hartung, HP; Kleinschnitz, C; Mausberg, AK; Meyer Zu Hörste, G; Stettner, M; Szepanowski, F; Warnke, C | 1 |
| Cai, T; Chitnis, T; Dahal, K; Hou, J; Kim, N; Weiner, H; Xia, Z | 1 |
| Conlon, N; Dunne, J; Gaughan, M; Holden, D; Redenbaugh, V; Redmond, J; Reynolds, A | 1 |
| Amato, MP; Battaglia, MA; Brambilla, L; Brescia Morra, V; Capobianco, M; Cavalla, P; Comi, G; De Luca, G; Ferraro, D; Filippi, M; Granella, F; Iaffaldano, P; Lepore, V; Lucisano, G; Lugaresi, A; Lus, G; Malucchi, S; Maniscalco, GT; Manni, A; Moiola, L; Montepietra, S; Mosconi, P; Paolicelli, D; Patti, F; Pesci, I; Petracca, M; Ponzio, M; Ragonese, P; Sola, P; Tedeschi, G; Toscano, S; Totaro, R; Trojano, M; Vianello, M | 1 |
| Aparasu, RR; Chikermane, SG; Earla, JR; Hutton, GJ; Li, J | 1 |
| Eisele, P; Gass, A; Platten, M; Schirmer, L; Weber, CE; Wittayer, M | 1 |
| Castagné, V; Debasly, S; Froget, G; Genest, L; Rupp, T | 1 |
| Boyko, AN | 1 |
| Affinito, G; Berera, G; Brescia Morra, V; Carotenuto, A; Lanzillo, R; Marrazzo, G; Moccia, M; Palladino, R; Petracca, M; Piscitelli, R; Triassi, M | 1 |
| Cano, S; Elliott, E; Jivraj, F; Kang, S; Kapadia, S; Reedie, S; Rock, M; Strzok, S | 1 |
| Ataei, S; Esfahani, ME; Jenabi, E; Sahraian, MA; Salehi, AM | 1 |
| Yukitake, M | 1 |
| Al-Iedani, O; Alshehri, A; Khormi, I; Koussis, N; Lea, R; Lechner-Scott, J; Ramadan, S | 1 |
| Comabella, M; Fissolo, N; Gutierrez, L; Montalban, X; Pappolla, A; Perez-Hoyos, S; Rio, J; Sanchez, A; Villar, LM | 1 |
| Benet, LZ; Liu, W; Wang, Z; Waubant, EL; Yu, Z; Zhai, S | 1 |
| Al-Asmi, A; Alroughani, R; Altintas, A; Ampapa, R; Blanco Morgado, Y; Butzkueven, H; Gerlach, O; Hodgkinson, S; Horakova, D; Kalincik, T; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, R; Oh, J; Ozakbas, S; Patti, F; Sanchez-Menoyo, JL; Soysal, A; Spelman, T; Spitaleri, D; Terzi, M; Tundia, N; Van Der Walt, A; van Pesch, V; Wong, SL; Yamout, B | 1 |
| Fukumoto, S; Isobe, N; Masaki, K; Matsushita, T; Tanaka, E; Watanabe, M; Yamasaki, R | 1 |
| Cocco, E; Fenu, G; Lorefice, L; Pilotto, S; Zoledziewska, M | 1 |
| Affinito, G; Brescia Morra, V; Carotenuto, A; Di Gennaro, M; Fumo, MG; Giordana, R; Lanzillo, R; Mercogliano, M; Moccia, M; Palladino, R; Petracca, M; Triassi, M | 1 |
| Aparasu, RR; Earla, JR; Hutton, GJ; Johnson, ML; Li, J | 1 |
| Alroughani, R; Barnett, M; Boz, C; Butler, E; Butzkueven, H; Buzzard, K; Duquette, P; Eichau, S; Garber, J; Gerlach, O; Girard, M; Grammond, P; Grand'Maison, F; Hodgkinson, S; Horakova, D; Izquierdo, G; Jokubaitis, V; Kalincik, T; Kermode, AG; Khoury, SJ; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, RAL; Merlo, D; Monif, M; Ozakbas, S; Patti, F; Prat, A; Prevost, J; Sa, MJ; Skibina, O; Slee, M; Terzi, M; van der Walt, A; Van Hijfte, L; Van Pesch, V; Van Wijmeersch, B; Weinstock-Guttman, B; Yamout, B; Zhou, Z; Zhu, C | 1 |
| Aguera-Morales, E; Al-Asmi, A; Al-Harbi, TM; Alroughani, R; Altintas, A; Ampapa, R; Bergamaschi, R; Boz, C; Butzkueven, H; Cartechini, E; Castillo-Trivino, T; Csepany, T; de Gans, K; Diouf, I; Duquette, P; Eichau, S; Ferraro, D; Gerlach, O; Gouider, R; Grammond, P; Grand'Maison, F; Granella, F; Gray, O; Hodgkinson, S; Horakova, D; Hughes, S; Iuliano, G; Kalincik, T; Kappos, L; Karabudak, R; Kubala Havrdova, E; Laureys, G; Lechner-Scott, J; Lugaresi, A; Malpas, CB; McCombe, PA; McGuigan, C; Onofrj, M; Ozakbas, S; Patti, F; Prat, A; Roos, I; Sa, MJ; Sánchez-Menoyo, JL; Sempere, AP; Sharmin, S; Shaw, C; Shaygannejad, V; Sidhom, Y; Slee, M; Sola, P; Solaro, C; Stuart, EA; Terzi, M; Treviño Frenk, I; van der Walt, A; Vucic, S; Yamout, B | 1 |
| Koca, N; Seferoğlu, M | 1 |
| Engin, E; Günal, D; Sünter, G; Vural, E; Yıldırım, KA | 1 |
| Axelsson, M; Brandt, AF; Carlin, G; Gafvelin, G; Grönlund, H; Hessa, T; Högelin, KA; Khademi, M; Kockum, I; Lycke, J; Malmeström, C; Olsson, T; Piehl, F; Rabenstein, M; Thomas, OG | 1 |
| Ahle, G; Bigaut, K; Collongues, N; Courtois, S; de Seze, J; Dentel, C; Fickl, A; Fleury, M; Gaultier, C; Kolitsi, I; Kremer, L; Lanotte, L; Moreau, A; Mostoufizadeh, S; Sellal, F | 1 |
| Baradaran, B; Barpour, N; Dabbaghi, R; Hosseinpourfeizi, M; Rahmani, S; Rajabi, A; Safaralizadeh, R | 1 |
| Benedetti, MD; Capobussi, M; Castellini, G; Featherstone, R; Filippini, G; Frau, S; Gonzalez-Lorenzo, M; Lucenteforte, E; Perduca, V; Tramacere, I; Virgili, G | 1 |
47 review(s) available for fingolimod hydrochloride and dimethyl fumarate
| Article | Year |
|---|---|
Novel oral agents for multiple sclerosis.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cladribine; Clinical Trials as Topic; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interferon beta-1b; Interferon-beta; Isoxazoles; Leflunomide; Minocycline; Multiple Sclerosis; Mycophenolic Acid; Propylene Glycols; Pyridones; Quinolones; Sphingosine | 2007 |
Multiple sclerosis therapies: molecular mechanisms and future.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Cladribine; Crotonates; Daclizumab; Dimethyl Fumarate; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Immunotherapy; Mice; Multiple Sclerosis; Myelin Basic Protein; Nitriles; Peptide Fragments; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Vaccines, DNA | 2010 |
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Topics: Administration, Oral; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
[Current treatment of multiple sclerosis].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cladribine; Dimethyl Fumarate; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Propylene Glycols; Quinolones; Sphingosine; Treatment Outcome | 2011 |
Oral treatment for multiple sclerosis.
Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
[Emerging therapies for multiple sclerosis].
Topics: 4-Aminopyridine; Administration, Oral; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Cladribine; Clinical Trials as Topic; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Middle Aged; Multicenter Studies as Topic; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Young Adult | 2013 |
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Topics: Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Disease Progression; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Randomized Controlled Trials as Topic; Recurrence; Sphingosine; Toluidines | 2014 |
A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunologic Factors; Multiple Sclerosis; Nitriles; Pregnancy; Pregnancy Outcome; Prenatal Exposure Delayed Effects; Propylene Glycols; Sphingosine; Toluidines | 2014 |
New management algorithms in multiple sclerosis.
Topics: Alemtuzumab; Algorithms; Antibodies, Monoclonal, Humanized; Clinical Protocols; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Peptides; Propylene Glycols; Sphingosine; Toluidines | 2014 |
Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis.
Topics: Administration, Oral; Animals; Blood-Brain Barrier; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immune System; Multiple Sclerosis; NF-E2-Related Factor 2; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2014 |
Is T-bet a potential therapeutic target in multiple sclerosis?
Topics: Animals; Antibodies, Monoclonal, Humanized; Dimethyl Fumarate; Drug Discovery; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Immunotherapy; Molecular Targeted Therapy; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine; T-Box Domain Proteins; Th17 Cells | 2014 |
Update on disease-modifying treatments for multiple sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Quality of Life; Rituximab; Toluidines; Treatment Outcome | 2014 |
Update on multiple sclerosis treatments.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Sphingosine; Toluidines | 2014 |
Current management of relapsing-remitting multiple sclerosis.
Topics: Administration, Intravenous; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Disease Progression; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Risk Assessment; Sphingosine; Toluidines | 2014 |
Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Disease Progression; Drug Approval; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Sphingosine; Toluidines; United States; United States Food and Drug Administration | 2015 |
[Oral treatments in multiple sclerosis].
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2014 |
New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Drug Approval; Drug Costs; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Nitriles; Polyethylene Glycols; Toluidines; United States; United States Food and Drug Administration | 2015 |
Newer agents in the treatment of multiple sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Toluidines; Treatment Outcome | 2015 |
Oral agents in multiple sclerosis.
Topics: Administration, Oral; Animals; Crotonates; Dimethyl Fumarate; Drug Approval; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Medication Adherence; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Toluidines | 2015 |
Induction and escalation therapies in multiple sclerosis.
Topics: Animals; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Induction Chemotherapy; Interferon-beta; Maintenance Chemotherapy; Mitoxantrone; Multiple Sclerosis; Natalizumab; Nitriles; Randomized Controlled Trials as Topic; Toluidines; Treatment Outcome | 2015 |
Novel Agents for Relapsing Forms of Multiple Sclerosis.
Topics: Adjuvants, Immunologic; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunoglobulin G; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Nitriles; Recurrence; Toluidines | 2016 |
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Topics: Alemtuzumab; Algorithms; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Toluidines | 2016 |
[Oral disease-modifying agents in relapsing-remitting multiple sclerosis].
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Toluidines | 2015 |
The use of immune modulating drugs for the treatment of multiple sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Molecular Targeted Therapy; Multiple Sclerosis; Natalizumab | 2016 |
The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
Topics: Animals; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Quinolones; Toluidines | 2016 |
Disease modifying therapies for relapsing multiple sclerosis.
Topics: Administration, Intravenous; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Daclizumab; Dimethyl Fumarate; Drug Substitution; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunoglobulin G; Immunologic Factors; Injections; Interferon-beta; Magnetic Resonance Imaging; Mitoxantrone; Multiple Sclerosis; Natalizumab; Nitriles; Toluidines | 2016 |
Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
Topics: Administration, Oral; Adult; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 2017 |
Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Interferons; Multiple Sclerosis, Relapsing-Remitting; Qatar | 2017 |
Update on disease-modifying therapies for multiple sclerosis.
Topics: Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Daclizumab; Dimethyl Fumarate; Drug Approval; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunoglobulin G; Immunologic Factors; Infusions, Intravenous; JC Virus; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Polyomavirus Infections; Recurrence; Toluidines; Treatment Outcome; Tumor Virus Infections; United States; United States Food and Drug Administration | 2017 |
Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Topics: Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Severity of Illness Index | 2017 |
What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
Topics: Administration, Oral; Animals; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunogenetics; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Toluidines | 2017 |
Effector and regulatory B cells in Multiple Sclerosis.
Topics: Alemtuzumab; Animals; B-Lymphocyte Subsets; B-Lymphocytes, Regulatory; Crotonates; Dimethyl Fumarate; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Natalizumab; Nitriles; Rituximab; Toluidines | 2017 |
Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Toluidines | 2017 |
Multiple sclerosis, a treatable disease .
Topics: Adjuvants, Immunologic; Alemtuzumab; Crotonates; Demyelinating Diseases; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Glucocorticoids; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Toluidines | 2017 |
Oral Therapies for Multiple Sclerosis.
Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Quinolones; Sphingosine 1 Phosphate Receptor Modulators; Toluidines | 2019 |
New biological agents in the treatment of multiple sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Cladribine; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Immunologic Factors; Immunosuppressive Agents; Indans; Multiple Sclerosis; Natalizumab; Neuromyelitis Optica; Oxadiazoles; Rituximab | 2018 |
Preapproval and postapproval evidence on drugs for multiple sclerosis.
Topics: 4-Aminopyridine; Alemtuzumab; Clinical Trials as Topic; Crotonates; Daclizumab; Dimethyl Fumarate; Drug Development; European Union; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Natalizumab; Nitriles; Polyethylene Glycols; Recurrence; Toluidines; Treatment Outcome | 2018 |
Adherence to oral disease-modifying therapy in multiple sclerosis patients: A systematic review.
Topics: Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Medication Adherence; Multiple Sclerosis; Nitriles; Toluidines | 2019 |
Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Interferon-beta; Multiple Sclerosis; Natalizumab; Nitriles; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Prospective Studies; Rituximab; Toluidines | 2020 |
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Betacoronavirus; CD8-Positive T-Lymphocytes; Cladribine; Coronavirus Infections; COVID-19; Crotonates; Cytokine Release Syndrome; Deprescriptions; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immune Evasion; Immunity, Innate; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Lymphopenia; Macrophages; Monocytes; Multiple Sclerosis; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2; Toluidines | 2020 |
Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic | 2021 |
Update on treatment in multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Algorithms; Antibodies, Monoclonal, Humanized; Cladribine; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Indans; Interferon-beta; Male; Mitoxantrone; Multiple Sclerosis; Natalizumab; Nitriles; Oxadiazoles; Pregnancy; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Toluidines | 2021 |
Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology.
Topics: Age Factors; Alemtuzumab; Animals; Coinfection; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Immunologic Factors; Immunosuppressive Agents; Immunotherapy; Infections; Natalizumab; Neurology; Risk Factors; Rituximab | 2021 |
Post marketing new adverse effects of oral therapies in multiple sclerosis: A systematic review.
Topics: Dimethyl Fumarate; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2022 |
[Progressive Multifocal Leukoencephalopathy: An Overview of Current Topics].
Topics: Antiviral Agents; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; JC Virus; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Natalizumab | 2022 |
Disease-modifying therapy for multiple sclerosis: Implications for gut microbiota.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Gastrointestinal Microbiome; Glatiramer Acetate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2023 |
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Topics: Adolescent; Adult; Alemtuzumab; Azathioprine; Cladribine; Daclizumab; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Immunotherapy; Interferon beta-1a; Interferon beta-1b; Male; Multiple Sclerosis; Natalizumab; Network Meta-Analysis; Rituximab; Young Adult | 2023 |
4 trial(s) available for fingolimod hydrochloride and dimethyl fumarate
| Article | Year |
|---|---|
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Crotonates; Dimethyl Fumarate; Disability Evaluation; Disease Progression; Evidence-Based Medicine; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Numbers Needed To Treat; Recurrence; Severity of Illness Index; Toluidines; Treatment Outcome | 2016 |
Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Product Surveillance, Postmarketing; Propensity Score; Retrospective Studies; Treatment Outcome; Young Adult | 2018 |
Electronic pill bottles to monitor and promote medication adherence for people with multiple sclerosis: A randomized, virtual clinical trial.
Topics: Adult; Dimethyl Fumarate; Electronics; Female; Fingolimod Hydrochloride; Humans; Medication Adherence; Middle Aged; Multiple Sclerosis | 2021 |
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
Topics: Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pregnancy; Recurrence | 2023 |
93 other study(ies) available for fingolimod hydrochloride and dimethyl fumarate
| Article | Year |
|---|---|
Drugs: An injection of hope.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal, Humanized; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Inflammation; Multiple Sclerosis; Natalizumab; Nitriles; Propylene Glycols; Quinolones; Risk Assessment; Sphingosine; Toluidines; United States; United States Food and Drug Administration | 2012 |
In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yes.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Interferons; Multiple Sclerosis; Natalizumab; Nitriles; Peptides; Propylene Glycols; Sphingosine; Toluidines | 2013 |
Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.
Topics: Adolescent; Adult; Cohort Studies; Cost-Benefit Analysis; Dimethyl Fumarate; Disability Evaluation; Female; Fingolimod Hydrochloride; Fumarates; Humans; Immunologic Factors; Injections, Intramuscular; Interferon beta-1a; Interferon-beta; Male; Markov Chains; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine; Young Adult | 2015 |
Recognizing and overcoming potential barriers to oral medications for MS.
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Sphingosine; Toluidines | 2014 |
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Adult; Crotonates; Dimethyl Fumarate; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Models, Statistical; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Outcome Assessment, Health Care; Patient Acuity; Randomized Controlled Trials as Topic; Recurrence; Toluidines | 2014 |
Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Topics: Cost-Benefit Analysis; Dimethyl Fumarate; Disability Evaluation; Disease Progression; England; Fingolimod Hydrochloride; Health Status; Humans; Immunosuppressive Agents; Markov Chains; Models, Econometric; Multiple Sclerosis, Relapsing-Remitting; Quality-Adjusted Life Years; State Medicine | 2015 |
Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Risk | 2016 |
Multiple rodent models and behavioral measures reveal unexpected responses to FTY720 and DMF in experimental autoimmune encephalomyelitis.
Topics: Animals; Dimethyl Fumarate; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Gait; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Motor Activity; Rats, Inbred Lew; Recognition, Psychology; Severity of Illness Index; Social Behavior; Time | 2016 |
Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Topics: Cost-Benefit Analysis; Delayed-Action Preparations; Dimethyl Fumarate; Disease Progression; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Markov Chains; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Quality-Adjusted Life Years | 2016 |
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies.
Topics: Adult; Aged; Case-Control Studies; CD56 Antigen; Cell Movement; Dimethyl Fumarate; Epstein-Barr Virus Nuclear Antigens; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Genetic Predisposition to Disease; Glatiramer Acetate; HLA-DRB1 Chains; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Polymorphism, Single Nucleotide; T-Box Domain Proteins; Young Adult | 2016 |
Features of Human CD3+CD20+ T Cells.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antigens, CD20; CD3 Complex; Cell Separation; Cytokines; Dimethyl Fumarate; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunologic Factors; Natalizumab; Real-Time Polymerase Chain Reaction; T-Lymphocyte Subsets; T-Lymphocytes | 2016 |
The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis.
Topics: Adult; Aged; Cross-Sectional Studies; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Health Surveys; Humans; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Patient Satisfaction; Surveys and Questionnaires | 2016 |
New oral drugs for the treatment of multiple sclerosis.
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Medication Therapy Management; Multiple Sclerosis; Nitriles; Toluidines; United Kingdom | 2016 |
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
Topics: Adult; Brain; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Patient Acceptance of Health Care; Retrospective Studies; Treatment Outcome | 2016 |
Novel Zebrafish EAE model: A quick in vivo screen for multiple sclerosis.
Topics: Animals; Dexamethasone; Dimethyl Fumarate; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Immunologic Factors; Phenotype; Sulfonamides; Thiazoles; Video Recording; Zebrafish | 2017 |
Oral Multiple Sclerosis Drugs Inhibit the
Topics: Anti-Bacterial Agents; Clostridium perfringens; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Hydroxybutyrates; Microbial Sensitivity Tests; Nitriles; Toluidines | 2017 |
Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
Topics: Alemtuzumab; Cost-Benefit Analysis; Dimethyl Fumarate; Drug Costs; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Polyethylene Glycols; United States | 2017 |
Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Topics: Adolescent; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Medicare; Medication Adherence; Multiple Sclerosis; Nitriles; Retrospective Studies; Toluidines; United States | 2017 |
Persistence to oral disease-modifying therapies in multiple sclerosis patients.
Topics: Adult; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Retrospective Studies; Statistics, Nonparametric; Toluidines; Treatment Outcome | 2017 |
Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Topics: Adult; Dimethyl Fumarate; Drug Substitution; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukocyte Count; Leukopenia; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Multiple Sclerosis; Prognosis; Prospective Studies; Retrospective Studies | 2018 |
Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
Topics: Adult; Cohort Studies; Community Health Planning; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Patient Selection; Rituximab; Sweden; Treatment Outcome | 2018 |
The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations.
Topics: Dimethyl Fumarate; Drug Utilization; Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis, Relapsing-Remitting; Off-Label Use; Rituximab | 2018 |
Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration.
Topics: Adult; Age Factors; Antibodies, Viral; Dimethyl Fumarate; Disability Evaluation; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Interferon-beta; Japan; JC Virus; Longitudinal Studies; Male; Multiple Sclerosis; Retrospective Studies; Sex Factors; Time Factors | 2018 |
New fungal infections associated with disease-modifying treatments in MS.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Mycoses; Natalizumab; Tinea | 2018 |
Rebound disease in multiple sclerosis.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2018 |
Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.
Topics: Adult; Contrast Media; Dimethyl Fumarate; Disease Progression; Drug Substitution; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Withholding Treatment | 2018 |
Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
Topics: Adult; Alemtuzumab; Dimethyl Fumarate; Employment; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Patient Reported Outcome Measures; Treatment Outcome | 2018 |
When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.
Topics: Adult; Alemtuzumab; Cost-Benefit Analysis; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Health Resources; Health Services; Humans; Immunosuppressive Agents; Male; Markov Chains; Models, Economic; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Technology Assessment, Biomedical | 2018 |
Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.
Topics: Adolescent; Adult; Aged; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Drug-Related Side Effects and Adverse Reactions; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Toluidines; Young Adult | 2018 |
Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
Topics: Adult; Cohort Studies; Crotonates; Delayed-Action Preparations; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Germany; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Interferons; Male; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Registries; Toluidines; Treatment Outcome | 2018 |
Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Topics: Administration, Oral; Adolescent; Adult; Aged; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Secondary Prevention; Toluidines; Treatment Outcome; United States; Young Adult | 2019 |
Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.
Topics: Adult; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Medication Adherence; Middle Aged; Multiple Sclerosis; Nitriles; Toluidines | 2019 |
Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.
Topics: Administration, Oral; Adult; Cohort Studies; Crotonates; Dimethyl Fumarate; Drug Prescriptions; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Insurance, Pharmaceutical Services; Male; Medication Adherence; Middle Aged; Multiple Sclerosis; Nitriles; Patient Preference; Retrospective Studies; Toluidines; United States; Young Adult | 2019 |
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
Topics: Adult; Cohort Studies; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propensity Score; Proportional Hazards Models; Recurrence; Toluidines | 2019 |
A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.
Topics: Canada; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Insurance Claim Review; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Patient Compliance; Retrospective Studies; Toluidines | 2019 |
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
Topics: Activities of Daily Living; Adolescent; Adult; Alemtuzumab; Cohort Studies; Crotonates; Dimethyl Fumarate; Disease Progression; Early Medical Intervention; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferons; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Retrospective Studies; Toluidines; Treatment Outcome; Young Adult | 2019 |
Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Topics: Alemtuzumab; Cladribine; Crotonates; Decision Support Techniques; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Recurrence; Risk Assessment; Toluidines | 2019 |
Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.
Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Recurrence; Treatment Outcome; Young Adult | 2019 |
Real-life use of oral disease-modifying treatments in Austria.
Topics: Administration, Oral; Adult; Austria; Cohort Studies; Crotonates; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propensity Score; Recurrence; Registries; Toluidines | 2019 |
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.
Topics: Adult; Crotonates; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Toluidines; Treatment Outcome | 2019 |
Th1Th17
Topics: Adult; Biomarkers; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Kaplan-Meier Estimate; Male; Multiple Sclerosis; T-Lymphocyte Subsets; Th17 Cells | 2019 |
Hepatitis E virus infections in patients with MS on oral disease-modifying treatment.
Topics: Administration, Oral; Adult; Chemical and Drug Induced Liver Injury; Demyelinating Diseases; Dimethyl Fumarate; Drug Substitution; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Hepatitis E; Hepatitis E virus; Humans; Immunosuppressive Agents; Interferon beta-1a; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Young Adult | 2019 |
Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.
Topics: Adult; Dimethyl Fumarate; Drug Substitution; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Treatment Outcome | 2019 |
Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients.
Topics: Adult; B-Lymphocytes; Cell Differentiation; Cells, Cultured; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Lymphocyte Activation; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2019 |
Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study.
Topics: Adult; Dimethyl Fumarate; Europe; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Recurrence; Retrospective Studies; Survival Analysis | 2020 |
Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
Topics: Algorithms; Bayes Theorem; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Models, Theoretical; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Precision Medicine; Prognosis; Recurrence; Treatment Adherence and Compliance | 2020 |
Changing therapeutic strategies and persistence to disease-modifying treatments in a population of multiple sclerosis patients from Veneto region, Italy.
Topics: Adult; Azathioprine; Dimethyl Fumarate; Drug Prescriptions; Drug Utilization; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Italy; Male; Medication Adherence; Middle Aged; Multiple Sclerosis; Time Factors | 2020 |
Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study.
Topics: British Columbia; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Laboratories; Male; Multiple Sclerosis; Pharmaceutical Preparations | 2021 |
Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
Topics: Adult; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Infections; Lymphocyte Count; Lymphocytes; Lymphopenia; Male; Multiple Sclerosis; Recurrence; Retrospective Studies; Risk | 2020 |
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study.
Topics: Aged; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Italy; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2020 |
Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
Topics: Administration, Oral; Adult; Austria; Crotonates; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Outcome Assessment, Health Care; Registries; Severity of Illness Index; Toluidines | 2020 |
[New Arrival of Disease Modifying Drugs Initiates New Era in Multiple Sclerosis Treatment in Japan].
Topics: Antibodies, Monoclonal, Humanized; Azetidines; Benzyl Compounds; Clinical Trials as Topic; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferons; Japan; Multiple Sclerosis; Natalizumab | 2020 |
COVID-19 in MS: Initial observations from the Pacific Northwest.
Topics: Adult; Aged; Coronavirus Infections; COVID-19; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunocompromised Host; Immunosuppressive Agents; Interferons; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Northwestern United States; Nursing Homes; Oregon; Pandemics; Pneumonia, Viral; Severity of Illness Index; Toluidines; Travel; Washington | 2020 |
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Topics: Adult; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Betacoronavirus; Coronavirus Infections; Cough; COVID-19; Cross-Sectional Studies; Crotonates; Dimethyl Fumarate; Disease Susceptibility; Dyspnea; Epidemics; Female; Fever; Fingolimod Hydrochloride; Glatiramer Acetate; Hospitalization; Humans; Hydroxybutyrates; Immunocompromised Host; Immunologic Factors; Intensive Care Units; Interferons; Iran; Lung; Lymphocyte Depletion; Male; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Rituximab; SARS-CoV-2; Severity of Illness Index; Toluidines; Tomography, X-Ray Computed | 2020 |
COVID-19 will change MS care forever - No.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Dimethyl Fumarate; Disease Management; Drug Substitution; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Interferon-beta; Multiple Sclerosis; Pandemics; Pneumonia, Viral; Rituximab; SARS-CoV-2; Telemedicine; Viral Vaccines | 2020 |
Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, CD19; B-Lymphocyte Subsets; B-Lymphocytes; Cross-Sectional Studies; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Flow Cytometry; Glatiramer Acetate; Humans; Immunologic Memory; Immunophenotyping; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Young Adult | 2020 |
Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.
Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Outcome Assessment, Health Care; Recurrence; Retrospective Studies; Rituximab | 2020 |
Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Betacoronavirus; Child; Coronavirus Infections; COVID-19; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunologic Factors; Interferon-beta; Kuwait; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Recurrence; Rituximab; SARS-CoV-2; Surveys and Questionnaires; Telephone; Toluidines; Young Adult | 2020 |
Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
The expression analyses of RMRP, DDX5, and RORC in RRMS patients treated with different drugs versus naïve patients and healthy controls.
Topics: Adult; Case-Control Studies; DEAD-box RNA Helicases; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon beta-1a; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nuclear Receptor Subfamily 1, Group F, Member 3; RNA, Long Noncoding; Young Adult | 2021 |
Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies.
Topics: Anosmia; Dimethyl Fumarate; Fatigue; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2022 |
Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study.
Topics: Administration, Oral; Adult; Crotonates; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Prospective Studies; Toluidines | 2021 |
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; COVID-19; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Immunologic Factors; Immunosuppressive Agents; Intensive Care Units; Interferons; Male; Middle Aged; Mortality; Multiple Sclerosis; Natalizumab; SARS-CoV-2; Severity of Illness Index; Young Adult | 2021 |
Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dimethyl Fumarate; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Symptom Flare Up | 2021 |
COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
Topics: COVID-19; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; SARS-CoV-2 | 2021 |
Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment.
Topics: Adult; Aged; Autoantibodies; Biomarkers; Dimethyl Fumarate; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunity, Humoral; Immunosuppressive Agents; Male; Myelin-Oligodendrocyte Glycoprotein; Myelitis, Transverse; Optic Neuritis; Recurrence; Seroconversion; Steroids; Treatment Outcome | 2021 |
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alemtuzumab; Azathioprine; Black or African American; Cladribine; Comorbidity; COVID-19; Crotonates; Cyclophosphamide; Cyclosporine; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Incidence; Interferon-beta; Logistic Models; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Mitoxantrone; Multiple Sclerosis; Mycophenolic Acid; Natalizumab; Nitriles; Obesity; Risk Factors; Rituximab; SARS-CoV-2; Toluidines; United States; White People; Young Adult | 2021 |
Multiple sclerosis hospitalizations among users of oral disease-modifying therapies.
Topics: Aged; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Hospitalization; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Toluidines; United States | 2021 |
Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
Topics: Adult; Aged; Alemtuzumab; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neoplasms; Nitriles; Outpatients; Proportional Hazards Models; Risk Factors; Smoking; Spain; Toluidines | 2021 |
Comparative effectiveness of dimethyl fumarate in multiple sclerosis.
Topics: Cohort Studies; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome | 2022 |
Proinflammatory CD20
Topics: Antigens, CD20; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Natalizumab; T-Lymphocyte Subsets | 2021 |
Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis.
Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Rituximab | 2021 |
The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis.
Topics: CD28 Antigens; Cell Proliferation; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Multiple Sclerosis; Pilot Projects; Treatment Outcome | 2022 |
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Topics: Adult; Age Factors; Case-Control Studies; COVID-19; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Odds Ratio; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sex Factors; Time Factors | 2022 |
FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS.
Topics: Adolescent; Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Retrospective Studies | 2022 |
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Iron; Magnetic Resonance Imaging; Multiple Sclerosis | 2022 |
Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Non-Small Cell Lung Cancer Preclinical Models.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lung Neoplasms; Mice; Tumor Microenvironment | 2022 |
[Comments on the GLIMPSE study on evaluating the efficacy of the drug cladribine in tablets in routine clinical practice in comparison with other tablet drugs for the pathogenetic treatment of multiple sclerosis].
Topics: Cladribine; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2022 |
Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Medication Adherence; Middle Aged; Multiple Sclerosis | 2022 |
The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study.
Topics: Cross-Sectional Studies; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Qualitative Research; Recurrence; Toluidines | 2022 |
Stability of longitudinal DTI metrics in MS with treatment of injectables, fingolimod and dimethyl fumarate.
Topics: Benchmarking; Brain; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; White Matter | 2023 |
Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis.
Topics: Chemokine CXCL13; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2023 |
Using an animal model to predict the effective human dose for oral multiple sclerosis drugs.
Topics: Animals; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Rats | 2023 |
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Topics: Cladribine; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Registries; Retrospective Studies; Tablets | 2023 |
Effect of smoking on disease activity in multiple sclerosis patients treated with dimethyl fumarate or fingolimod.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Smoking | 2023 |
Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020.
Topics: Dimethyl Fumarate; Female; Fertility; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Natalizumab; Pregnancy | 2023 |
Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis.
Topics: Adult; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Medication Adherence; Multiple Sclerosis; Retrospective Studies | 2023 |
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neoplasm Recurrence, Local; Recurrence | 2023 |
Effects of disease-modifying therapies on lipid parameters in patients with multiple sclerosis.
Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2023 |
Real-life outcomes for oral disease-modifying treatments of relapsing-remitting multiple sclerosis patients: Adherence and adverse event profiles from Marmara University.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Universities | 2023 |
The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
Topics: Adaptive Immunity; Alemtuzumab; Antibodies; Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Interferon-gamma; Multiple Sclerosis; Natalizumab; SARS-CoV-2; Vaccination | 2023 |
Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study.
Topics: Adolescent; Child; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon beta-1a; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2023 |
The effect of glatiramer acetate, IFNβ-1a, fingolimod, and dimethyl fumarate on the expression of T-bet, IFN-γ, and MEG3 in PBMC of RRMS patients.
Topics: Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferon-gamma; Leukocytes, Mononuclear; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neurodegenerative Diseases | 2023 |